Volume 95 Issue 37 | p. 13 | Concentrates
Issue Date: September 18, 2017

Janssen drops hepatitis C treatment

By Ryan Cross
Department: Business
Keywords: Drug development, Janssen, Johnson & Johnson, hepatitis C, Achillion

Johnson & Johnson’s Janssen division says it will halt development of the hepatitis C treatment JNJ-4178, citing rising numbers of existing therapies. JNJ-4178 is a cocktail of three small-molecule antivirals: AL-335, obtained when Janssen acquired Alios BioPharma for $1.75 billion; simeprevir, licensed from Medivir; and odalasvir from Achillion Pharmaceuticals. Share prices at Medivir and Achillion fell by double digits after the news. Janssen says it will shift emphasis toward hepatitis B therapies.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment